New Treatment Strategy May Eliminate Need for Immediate Organ Removal As reported on Bioengineer, groundbreaking clinical investigation led by researchers at Mayo Clinic suggests that an innovative intravesical immunological agent…
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated…
As reported on Business Wire, Onchilles Pharma has announced the first patient dosing in a Phase 1/2 clinical trial evaluating its investigational therapy, N17350, in individuals with advanced solid tumors.…
As reported on STAT News, a novel combination of investigational therapies from Tango Therapeutics and Revolution Medicines is generating cautious optimism after demonstrating notable tumor responses in an early-stage clinical…
As reported on Business Wire, Stanford Medicine Cancer Center has reported a significant milestone in radiation oncology, completing the world’s first patient treatment using a compact upright proton therapy system.…
By Dr. Avishek Kumar When someone hears there may finally be a breakthrough for pancreatic cancer, the natural reaction is hope. In clinic, however, I often see what comes next.…
As reported on PharmaTimes, Poolbeg Pharma has secured a Canadian patent protecting the use of p38 MAPK inhibitors, including its lead candidate POLB 001, for preventing cytokine release syndrome (CRS) associated…
While surgery has long been the standard for removing solid tumors, a revolutionary technique called histotripsy is offering an alternative, as reported on MedPage Today. Histotripsy uses high-intensity, focused ultrasound…
As reported on ScienceDaily, a research team at the Icahn School of Medicine at Mount Sinai has unveiled a novel immunotherapy that tackles metastatic cancer by attacking the tumor’s protective…
As reported on BioPharmaDive, new clinical trial data presented at the American Society of Hematology (ASH) annual meeting suggests that an early treatment regimen combining Tecvayli (Johnson & Johnson’s bispecific…
Written by Maria Palombini Answer: at the time of diagnosis, it should be one of the first actions you, the patient and/or caregiver, should take. Why? Receiving a diagnosis with…
Astellas Pharma Inc. has announced that its Phase 2 GLEAM trial evaluating zolbetuximab in combination with gemcitabine plus nab-paclitaxel for metastatic pancreatic adenocarcinoma did not meet its primary endpoint of…
Jazz Pharmaceuticals plc has taken a major leap in rare cancer treatment with the recent FDA accelerated approval of Modeyso (dordaviprone), the first-ever therapy for relapsed H3 K27M-mutated diffuse midline…
In a breakthrough study, scientists have uncovered a surprising ally in the fight against cancer: the bacteria living within tumors. According to World Pharma News, an international team led by…
Dewpoint Therapeutics, a U.S.-based biotechnology innovator, has announced the successful closure of its Series D financing round. As reported by thepharmaletter, Dewpoint Therapeutics is renowned for its pioneering work in…
Eli Lilly’s breast cancer drug Verzenio (abemaciclib) has achieved a significant milestone, with new study results showing it helps people with a common form of early-stage breast cancer live longer.…
Shebli Atrash, MD, Levine Cancer Institute medical oncologist and associate professor of medicine at the University of Wake Forest interviewed with Medical Express following his presentation at the 2025 Conference in…
Vepdegestrant, an investigational oral selective estrogen receptor degrader (SERD), has reached a critical milestone as the U.S. Food and Drug Administration (FDA) reviews its New Drug Application (NDA) for use…
Recent advancements in the treatment of metastatic urothelial cancer (mUC) have dramatically improved patient outcomes, primarily due to the introduction of antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs). According…
In a significant advancement for cancer treatment, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Bavencio (avelumab) for the treatment of patients with locally advanced or…
Lancet Oncology Recently published reports updating the findings from the phase 3 DREAMM 7 trial involving 494 patients averaging ages 64.5 years with the median follow-up of 39.4 months. Accordingly, patients…
Novel radioactive medicine may be an inconvenient read for many people, but if you or someone you care about has metastatic breast cancer the words will soon become part of…
Calidi Biotherapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation to its experimental therapy, CLD-201 SuperNova, for the treatment of glioblastoma.…
Immunotherapy, once considered a niche treatment, has rapidly become a central pillar in the fight against cancer. As detailed in a recent article from Becker’s Hospital Review, this innovative approach…
ScanCell, a biotech firm focused on immunotherapies, announced promising results from Phase 2 clinical trials for its skin cancer vaccines, but only one of its two candidates will advance to…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
